Evidence map›Paper›PMID 32918123›Full record

Trial reportMolecular biology reports2020

The impact of CYP2D6*4 and GSTP1 Ile105Val polymorphisms on the susceptibility to develop BCR-ABL1 negative myeloproliferative neoplasms.

Aynur Daglar-Aday, Basak Akadam-Teker, Ipek Yonal-Hindilerden, Hasan Dermenci, Ezgi Sahin, Fehmi Hindilerden, Hulya Yilmaz-Aydogan, Oguz Ozturk, Akif Selim Yavuz

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Molecular biology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Aynur Daglar-AdayDivision of Medical Genetics, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Capa, 34093, Istanbul, Turkey. aynur.aday@istanbul.edu.tr.ORCID http://orcid.org/0000-0001-8072-0646
Basak Akadam-TekerDepartment of Medical Genetics, Faculty of Medicine, Giresun University, Giresun, Turkey.ORCID http://orcid.org/0000-0003-3618-0560
Ipek Yonal-HindilerdenDivision of Hematology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-1353-2367
Hasan DermenciDivision of Hematology, Department of Internal Medicine, Haydarpaşa Numune Training and Research Hospital, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-2244-5006
Ezgi SahinDepartment of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-6162-8983
Fehmi HindilerdenHematology Clinic, Istanbul Bakırkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-6297-9555
Hulya Yilmaz-AydoganDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-8837-6664
Oguz OzturkDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-2439-9269
Akif Selim YavuzDivision of Hematology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-9049-4654
Istanbul University · TRBakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi · TRGiresun University · TRHaydarpaşa Numune Eğitim ve Araştırma Hastanesi · TR

Funding

Bilimsel Araştirma Projeleri Birimi, Istanbul Üniversitesi 23924
6 · The paper itself

Abstract

Inter-individual variations in the genes encoding xenobiotic-metabolizing enzymes have been reported to alter susceptibility to various diseases involving hematological disorders. The purpose of this case-control study was to investigate the relationship between CYP2D6*4 and GSTP1 Ile105Val polymorphisms and the risk of developing BCR-ABL1 negative myeloproliferative neoplasms (MPN). PCR-RFLP was used for genotyping single nucleotide polymorphisms (SNP) in CYP2D6 and GSTP1 in 139 patients with MPN and 126 controls. There was a significantly increased risk for developing BCR-ABL1 negative MPN for the group bearing the CYP2D6*4 variant allele (X

Indexed as

Mutation, MissensePolymorphism, Single NucleotideAdultAgedAllelesAmino Acid SubstitutionCytochrome P-450 CYP2D6FemaleFollow-Up StudiesFusion Proteins, bcr-ablGlutathione S-Transferase piHematologic NeoplasmsHumansMaleMiddle AgedMyeloproliferative DisordersBCR-ABL1 fusion protein, humanCytochrome P-450 CYP2D6Fusion Proteins, bcr-ablGlutathione S-Transferase piGSTP1 protein, humanCYP2D6*4GSTP1 Ile105ValMyeloproliferative neoplasmsPolymorphismXenobiotics

Identifiers

PMID32918123
OpenAlexW3084513834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.